Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene receives EU approval for new myeloma drug

Celgene receives EU approval for new myeloma drug

9th August 2013

Celgene has announced that it has received European Commission approval for its new blood cancer drug pomalidomide.

The regulatory body has ratified the compound for use in combination with dexamethasone for adult patients with relapsed and refractory multiple myeloma who have have demonstrated disease progression despite receiving at least two prior therapies, including both lenalidomide and bortezomib.

Data from the phase III trial MM-03 that demonstrated the drug's progression-free survival benefits formed the basis of the European Commission's decision.

Following this announcement, Celgene plans to launch the product in Europe under the trade name Imnovid.

Alan Colowick, president of Celgene in Europe, the Middle East and Africa, said: "With today's approval, Celgene becomes one of the few companies to deliver treatments across all stages of multiple myeloma, right from the start at diagnosis."

This comes after the firm announced positive trial data earlier this week that showed the benefits its drug Revlimid can offer in the treatment of smouldering multiple myeloma.ADNFCR-8000103-ID-801623027-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.